Active, not recruitingPhase 3NCT05429268

Study to Evaluate the Safety and Efficacy of Tafasitamab Plus Lenalidomide in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (firmMIND)

Studying Anorectal malformation

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Incyte Corporation
Principal Investigator
Oliver Manzke, MD
Incyte Corporation
Intervention
Tafasitamab(drug)
Enrollment
82 target
Eligibility
18-99 years · All sexes
Timeline
20222027

Study locations (30)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT05429268 on ClinicalTrials.gov

Other trials for Anorectal malformation

Additional recruiting or active studies for the same condition.

See all trials for Anorectal malformation

← Back to all trials